Penumbra (medical company)

The Global Digital Health Market to Surpass USD 486 Billion by 2027 | DelveInsight

Retrieved on: 
Wednesday, February 22, 2023

LAS VEGAS, Feb. 22, 2023 /PRNewswire/ -- DelveInsight's Digital Health Market Insights report provides the current and forecast market analysis, individual leading digital health companies' market shares, challenges, digital health market drivers, barriers, and trends, and key digital health companies in the market.

Key Points: 
  • Furthermore, the growing patient pool suffering from chronic disease and the growing burden of the global geriatric population will increase the need for remote and virtual patient care, resulting in increased demand for digital health
    LAS VEGAS, Feb. 22, 2023 /PRNewswire/ -- DelveInsight's Digital Health Market Insights report provides the current and forecast market analysis, individual leading digital health companies' market shares, challenges, digital health market drivers, barriers, and trends, and key digital health companies in the market.
  • As per DelveInsight estimates, North America is anticipated to dominate the global digital health market during the forecast period.
  • To know more about why North America is leading the market growth in the digital health market, get a snapshot of the Digital Health Market Outlook
    The rising demand for digital health to achieve remote and virtual patient care and monitoring across the globe is one of the key factors driving the digital health market.
  • Moreover, the government's supportive initiatives, rising demand for digital health services, particularly remote patient monitoring, and the expansion of venture capitalist investments in the digital health market will all positively affect digital health market growth.

The Global Digital Health Market to Surpass USD 486 Billion by 2027 | DelveInsight

Retrieved on: 
Wednesday, February 22, 2023

LAS VEGAS, Feb. 22, 2023 /PRNewswire/ -- DelveInsight's Digital Health Market Insights report provides the current and forecast market analysis, individual leading digital health companies' market shares, challenges, digital health market drivers, barriers, and trends, and key digital health companies in the market.

Key Points: 
  • Furthermore, the growing patient pool suffering from chronic disease and the growing burden of the global geriatric population will increase the need for remote and virtual patient care, resulting in increased demand for digital health
    LAS VEGAS, Feb. 22, 2023 /PRNewswire/ -- DelveInsight's Digital Health Market Insights report provides the current and forecast market analysis, individual leading digital health companies' market shares, challenges, digital health market drivers, barriers, and trends, and key digital health companies in the market.
  • As per DelveInsight estimates, North America is anticipated to dominate the global digital health market during the forecast period.
  • To know more about why North America is leading the market growth in the digital health market, get a snapshot of the Digital Health Market Outlook
    The rising demand for digital health to achieve remote and virtual patient care and monitoring across the globe is one of the key factors driving the digital health market.
  • Moreover, the government's supportive initiatives, rising demand for digital health services, particularly remote patient monitoring, and the expansion of venture capitalist investments in the digital health market will all positively affect digital health market growth.

SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"

Retrieved on: 
Monday, December 19, 2022

SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.

Key Points: 
  • SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.
  • SinoMab is the first Hong Kong-based listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics, primarily monoclonal antibody ("mAb")-based biologics, for the treatment of immunological diseases.
  • Currently, various candidate products for all-field indications of autoimmune diseases in SinoMab's layout have started clinical trials successively and are progressing steadily.
  • Previously, SinoMab appointed Mr. Shanchun WANG as the President (China) of the Company, mainly responsible for the China operation.